戻る Agenda
Benchmarking and Identifying Opportunities to Improve Intentional Dose Non-Adherence in Clinical Trials
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development
Tufts University School of Medicine, United States
The results of a groundbreaking study quantifying intentional dose non-adherence are presented followed by a discussion among a panel of clinical and regulatory professionals on the implications of the findings.
Learning Objective : Quantify intentional dose non-adherence rates in clinical trials; Identify factors associated with, and predictive of intentional non-adherence; Discuss policies and solutions to address and reduce intentional non-adherence.
Speaker(s)
Quantifying the Magnitude of Intentional Dose Non Adherence
Kenneth Getz, MBA
Tufts University School of Medicine, United States
Tufts Center for the Study of Drug Development
Accounting For and Managing Dose Non-Adherence in Clinical Trials
Marlen Rattiner, MA
AiCure, United States
Vice President, Product Management